Grape King Bio Ltd - Asset Resilience Ratio
Grape King Bio Ltd (1707) has an Asset Resilience Ratio of 0.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 1707 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Grape King Bio Ltd's Asset Resilience Ratio has changed over time. See Grape King Bio Ltd (1707) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Grape King Bio Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 1707 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$113.04 Million | 0.72% |
| Total Liquid Assets | NT$113.04 Million | 0.72% |
Asset Resilience Insights
- Limited Liquidity: Grape King Bio Ltd maintains only 0.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grape King Bio Ltd Industry Peers by Asset Resilience Ratio
Compare Grape King Bio Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Grape King Bio Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Grape King Bio Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.72% | NT$113.04 Million ≈ $3.56 Million |
NT$15.74 Billion ≈ $495.84 Million |
+0.13pp |
| 2024-12-31 | 0.58% | NT$89.41 Million ≈ $2.82 Million |
NT$15.32 Billion ≈ $482.78 Million |
-0.39pp |
| 2023-12-31 | 0.97% | NT$151.21 Million ≈ $4.76 Million |
NT$15.51 Billion ≈ $488.71 Million |
+0.20pp |
| 2022-12-31 | 0.78% | NT$117.05 Million ≈ $3.69 Million |
NT$15.05 Billion ≈ $474.25 Million |
-1.09pp |
| 2021-12-31 | 1.87% | NT$262.24 Million ≈ $8.26 Million |
NT$14.06 Billion ≈ $442.99 Million |
+1.27pp |
| 2020-12-31 | 0.59% | NT$77.66 Million ≈ $2.45 Million |
NT$13.10 Billion ≈ $412.85 Million |
-0.16pp |
| 2019-12-31 | 0.76% | NT$85.82 Million ≈ $2.70 Million |
NT$11.36 Billion ≈ $357.87 Million |
+0.40pp |
| 2018-12-31 | 0.36% | NT$38.21 Million ≈ $1.20 Million |
NT$10.65 Billion ≈ $335.47 Million |
-2.17pp |
| 2017-12-31 | 2.53% | NT$250.45 Million ≈ $7.89 Million |
NT$9.89 Billion ≈ $311.64 Million |
-1.55pp |
| 2016-12-31 | 4.08% | NT$389.45 Million ≈ $12.27 Million |
NT$9.55 Billion ≈ $300.87 Million |
-4.36pp |
| 2015-12-31 | 8.44% | NT$726.59 Million ≈ $22.89 Million |
NT$8.61 Billion ≈ $271.34 Million |
+4.60pp |
| 2014-12-31 | 3.84% | NT$205.97 Million ≈ $6.49 Million |
NT$5.37 Billion ≈ $169.15 Million |
-5.32pp |
| 2013-12-31 | 9.16% | NT$423.81 Million ≈ $13.35 Million |
NT$4.63 Billion ≈ $145.83 Million |
-1.58pp |
| 2012-12-31 | 10.74% | NT$415.31 Million ≈ $13.08 Million |
NT$3.87 Billion ≈ $121.87 Million |
+1.99pp |
| 2011-12-31 | 8.74% | NT$302.13 Million ≈ $9.52 Million |
NT$3.46 Billion ≈ $108.87 Million |
-0.12pp |
| 2010-12-31 | 8.86% | NT$283.78 Million ≈ $8.94 Million |
NT$3.20 Billion ≈ $100.86 Million |
-11.98pp |
| 2009-12-31 | 20.85% | NT$668.14 Million ≈ $21.05 Million |
NT$3.21 Billion ≈ $100.98 Million |
-1.26pp |
| 2008-12-31 | 22.10% | NT$571.49 Million ≈ $18.01 Million |
NT$2.59 Billion ≈ $81.47 Million |
-1.76pp |
| 2007-12-31 | 23.86% | NT$602.68 Million ≈ $18.99 Million |
NT$2.53 Billion ≈ $79.59 Million |
+7.68pp |
| 2006-12-31 | 16.18% | NT$402.00 Million ≈ $12.67 Million |
NT$2.48 Billion ≈ $78.28 Million |
-6.33pp |
| 2005-12-31 | 22.51% | NT$533.12 Million ≈ $16.80 Million |
NT$2.37 Billion ≈ $74.61 Million |
+8.51pp |
| 2004-12-31 | 14.00% | NT$343.66 Million ≈ $10.83 Million |
NT$2.45 Billion ≈ $77.34 Million |
+6.00pp |
| 2003-12-31 | 8.00% | NT$184.75 Million ≈ $5.82 Million |
NT$2.31 Billion ≈ $72.78 Million |
+4.12pp |
| 2002-12-31 | 3.87% | NT$96.18 Million ≈ $3.03 Million |
NT$2.48 Billion ≈ $78.21 Million |
-- |
About Grape King Bio Ltd
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; a… Read more